Infinity Pharmaceuticals, Inc. (INFI) Announces Phase I Clinical Trial for IPI-926
Infinity Pharmaceuticals, Inc. (NASD: INFI), an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions, recently announced that the company has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926. The Phase 1 trial is an open-label, dose-escalation study evaluating IPI-926 in up to 50 patients with advanced and/or metastatic solid tumors. IPI-926 is a proprietary inhibitor of the Hedgehog signaling pathway that binds to and inhibits a key regulator of this pathway, the Smoothened receptor. The Hedgehog signaling…